EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

First‐Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management

Bojan Tepes iD, Nataša Brglez Jurečič, Maja Denkovski, Miroslav Vujasinovič, Zdenko Kikec, Jurij Bednarik, Katja Tepes, Anna Cano-Català, Pablo Parra, Leticia Moreira, Olga P Nyssen, Francis Mégraud und 2 weitere

Helicobacter · 2025

DOI: 10.1111/hel.70029 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Helicobacter, 2025. Verfasst von Bojan Tepes und 13 weiteren Autor:innen. Beteiligte Einrichtung: Diagnostic Center, Rogaška Slatina, Slovenia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Helicobacter Infections, Helicobacter pylori. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: EHMSG, AEG Foundation, HORIZON EUROPE Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment is indicated for all Helicobacter pylori infections. However, the best approach for H. pylori management remains unclear.

Methods

H. pylori eradication data from Hp‐EuReg on treatment‐naive patients in Slovenia from 2013 to 2023 were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence, and safety were analyzed. The effectiveness was assessed by modified intention to treat (mITT).

Results

Eight Slovenian medical institutions contributed data for 4016 treatment‐naive patients to Hp‐EuReg. Of these, 18% did not undergo confirmatory post‐treatment; most who did received a urea breath test. Between 2013 and 2018, 7‐day triple therapy with amoxicillin and clarithromycin was most frequently used in first‐line treatment, with an 88% eradication rate. From 2019 to 2023, a 14‐day high‐dose PPI (esomeprazole 40 mg b.i.d.) triple therapy with amoxicillin and clarithromycin was used, showing a significantly higher effectiveness at 94% ( p < 0.05). Quadruple bismuth‐based therapy (esomeprazole 40 mg b.i.d., plus amoxicillin 500 mg, metronidazole 400 mg, and bismuth 120 mg, all q.i.d.) provided a 96.9% eradication rate, though this was not significantly better than the 14‐day triple regimen. The H. pylori resistance rate to clarithromycin was 16% from 2013 to 2018, dropping to 13.5% from 2019 to 2023. Side effects were reported by 9.6% of patients, and treatment compliance was > 99%.

Conclusions

The study suggests that systematic data collection from routine clinical practice in Hp‐EuReg can guide first‐line H. pylori treatment. Established 90% treatment effectiveness threshold may serve as a surrogate marker for monitoring H. pylori resistance rates to antibiotics. In countries with a H. pylori resistance rate < 15%, such as Slovenia, the 14‐day high‐dose PPI amoxicillin‐clarithromycin regimen is an optimal first‐line empirical treatment. Trial Registration: NCT02328131

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsHelicobacter InfectionsHelicobacter pyloriAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAmoxicillinClarithromycinDrug Therapy, CombinationProton Pump InhibitorsRegistriesSloveniaTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriHp‐EuRegSloveniaeradication treatment

Substanzen

AmoxicillinAnti-Bacterial AgentsClarithromycinProton Pump Inhibitors

Autor:innen und Institutionen

  • Diagnostic Center, Rogaška Slatina, Slovenia.
  • Diagnostic Center, Bled, Slovenia.
  • General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia.
  • Klinika Doktor 24, Ljubljana, Slovenia.
  • Gastrointestinal Oncology, Endoscopy and Surgery (GOES) Research Group, Althaia Xarxa Assistencial Universitària de Manresa, Institut de Recerca i Innovació en Ciències de la Vida i de la Salut de la Catalunya Central (…
  • Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Madrid, Spain.

ORCID-Profile: Bojan Tepes

Förderung

  • EHMSG
  • AEG Foundation
  • HORIZON EUROPE Health
  • UK Research and innovation
  • EU4Health
  • DIASORIN
  • JUVISE
  • BIOCIDEX

Zitieren

APA

Tepes, B., Jurečič, N. B., Denkovski, M., Vujasinovič, M., Kikec, Z., Bednarik, J., Tepes, K., Cano-Català, A., Parra, P., Moreira, L., Nyssen, O. P., Mégraud, F., O'Morain, C., & Gisbert, J. P. (2025). First‐Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management. Helicobacter. https://doi.org/10.1111/hel.70029

Vancouver

Tepes B, Jurečič NB, Denkovski M, Vujasinovič M, Kikec Z, Bednarik J, et al. First‐Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management. Helicobacter. 2025. doi:10.1111/hel.70029

BibTeX
@article{Tepes2025,
  author = {Tepes, Bojan and Jurečič, Nataša Brglez and Denkovski, Maja and Vujasinovič, Miroslav and Kikec, Zdenko and Bednarik, Jurij and Tepes, Katja and Cano-Català, Anna and Parra, Pablo and Moreira, Leticia and Nyssen, Olga P and Mégraud, Francis and O'Morain, Colm and Gisbert, Javier P},
  title = {First‐Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management},
  journal = {Helicobacter},
  year = {2025},
  doi = {10.1111/hel.70029}
}
Kostenlos starten →